Next Article in Journal
An Integrated Outlook on the Metagenome and Metabolome of Intestinal Diseases
Next Article in Special Issue
Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future
Previous Article in Journal / Special Issue
Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma
Open AccessReview

New Tools for Molecular Therapy of Hepatocellular Carcinoma

1
Department of Cellular Biotechnologies and Hematology, Pasteur Institute-Cenci Bolognetti Foundation, Sapienza University of Rome, Viale Regina Elena, 324, 00161 Rome, Italy
2
National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Via Portuense, 292, 00149 Rome, Italy
*
Authors to whom correspondence should be addressed.
Academic Editor: Stephen L. Chan
Diseases 2015, 3(4), 325-340; https://doi.org/10.3390/diseases3040325
Received: 15 September 2015 / Revised: 15 October 2015 / Accepted: 22 October 2015 / Published: 30 October 2015
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, arising from neoplastic transformation of hepatocytes or liver precursor/stem cells. HCC is often associated with pre-existing chronic liver pathologies of different origin (mainly subsequent to HBV and HCV infections), such as fibrosis or cirrhosis. Current therapies are essentially still ineffective, due both to the tumor heterogeneity and the frequent late diagnosis, making necessary the creation of new therapeutic strategies to inhibit tumor onset and progression and improve the survival of patients. A promising strategy for treatment of HCC is the targeted molecular therapy based on the restoration of tumor suppressor proteins lost during neoplastic transformation. In particular, the delivery of master genes of epithelial/hepatocyte differentiation, able to trigger an extensive reprogramming of gene expression, could allow the induction of an efficient antitumor response through the simultaneous adjustment of multiple genetic/epigenetic alterations contributing to tumor development. Here, we report recent literature data supporting the use of members of the liver enriched transcription factor (LETF) family, in particular HNF4α, as tools for gene therapy of HCC. View Full-Text
Keywords: HCC; HNF4α; LETFs; miRNAs; TGFβ; EMT; gene therapy HCC; HNF4α; LETFs; miRNAs; TGFβ; EMT; gene therapy
Show Figures

Figure 1

MDPI and ACS Style

Marchetti, A.; Bisceglia, F.; Cozzolino, A.M.; Tripodi, M. New Tools for Molecular Therapy of Hepatocellular Carcinoma. Diseases 2015, 3, 325-340.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop